MedPath

Study of Magnetic Fields for Treatment of Parkinson's Disease

Phase 2
Completed
Conditions
Parkinson's Disease
Interventions
Device: The Resonator control
Device: The Resonator
Registration Number
NCT00779155
Lead Sponsor
pico-tesla Magnetic Therapies, LLC
Brief Summary

The purpose of this study is to determine if low level magnetic fields may help to relieve symptoms of Parkinson's disease.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • idiopathic PD with motor fluctuations of at least 3-4 hours daily., Subject on levodopa, subject is ambulatory, maintain regular med schedule, willing and able to abstain from new PD treatments, Able to demonstrate correct completion of PD diaries, non-demented, adequate contraceptive measures, capable of giving full written consent.
Exclusion Criteria
  • any factors that will prevent subject from completing full course of therapy with the resonator, any factors preventing subject from attending clinic in the "off" state, atypical parkinsonism, no active brain tumors, strokes, hydrocephalus, any other neurologic or non-neurologic disorder which might affect the symptomatic expression of pts. parkinsonism, suffers from chronic pain, no meds that may produce parkinsonism, no psychiatric disturbance, Epilepsy, HIV, Cancer, History of ECT, Diabetic Neuropathy, Uncontrolled HTN, Advanced Pulmonary Disease, Known heart conditions such as cardiac arrythmias, previous PD surgical interventions, prosthetics comprised of ferrous metals, pacemakers, DBS, Uncontrolled, unstable or untreated medical illnesses, Consumption of more than 21 alcoholic drinks per week, Pregnant, breast feeding, developmental disability

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Inactive Resonator TherapyThe Resonator controlInactive magnetic resonance therapy
Active Resonator TherapyThe Resonatoractive magnetic resonance therapy
Primary Outcome Measures
NameTimeMethod
Change From Baseline to Study End Point in the Combined Scores From the UPDRS Subscale II and III Recorded in the Subjects "on" State.Baseline and 8 weeks

The UPDRS is used to measure different aspects of Parkinson's Disease (PD). The UPDRS subscale II assesses how PD affects a person's daily life, with scores ranging from 0-52, with 52 representing greatest severity. The UPDRS subscale III assesses how PD affects how a person moves about, with scores ranging from 0-108, with 108 representing greatest severity. The combination of these 2 scores is used in clinical trials and in clinical practice to get a good overall idea of how PD affects a person's life. Combined score ranges from 0-160, with 160 being greatest severity.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

pico-tesla Magnetic Therapies

🇺🇸

Littleton, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath